Anaplastic oligodendroglioma
MONDO:0016696A WHO grade III oligodendroglioma with focal or diffuse malignant morphologic features (prominent nuclear pleomorphism, mitoses, and increased cellularity).
Also known as: WHO grade III oligodendroglial neoplasm, WHO grade III oligodendroglial tumor, WHO grade III oligodendroglial tumour, anaplastic oligodendroglioma, malignant oligodendroglioma, oligodendroglioma, anaplastic, malignant, oligodendroglioma, malignant, undifferentiated oligodendroglioma
2841 clinical trials for this condition and its sub-types, 22 tagged with Anaplastic oligodendroglioma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Anaplastic oligodendroglioma
-
IDH-mutant and 1p/19q-codeleted oligodendroglioma 9 trials · 13 incl. sub-types
2 sub-types
-
New combo aims to tackle aggressive brain tumors that have come back
Disease control Recruiting nowThis early-phase study tests a new two-drug combination for adults whose high-grade glioma (a fast-growing brain tumor) has returned after standard treatment. The drugs are temozolomide (a chemotherapy pill given daily at low doses) and abexinostat (an experimental drug that may …
Phase 1 • Sponsor: University of Nebraska • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New combo therapy targets aggressive brain tumors in phase 2 trial
Disease control Recruiting nowThis study tests a more intense treatment for a fast-growing type of brain cancer called IDH wildtype glioma. It combines higher doses of radiation with the chemotherapy drug temozolomide to try to stop the tumor from growing longer. The trial will enroll 40 adults with this spec…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Promising drug combo targets Hard-to-Treat brain cancers
Disease control Recruiting nowThis study tests two drugs—retifanlimab (an immunotherapy) and DFMO (a growth blocker)—alone or together in 33 adults with progressive high-grade glioma, an aggressive brain cancer. The goal is to find the safest, most effective dose and see if the combination boosts the immune s…
Phase 1/2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
Could a daily pastille help fight recurrent brain tumors?
Disease control Recruiting nowThis pilot study tests whether adding APG-157 (a pastille dissolved in the mouth) to standard bevacizumab can help people with recurrent high-grade glioma. About 30 participants will take APG-157 three times daily while continuing bevacizumab. The study tracks survival, tumor res…
Phase 1/2 • Sponsor: Aveta Biomics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New study tests if proton radiation can spare brain tissue without hurting survival
Disease control Recruiting nowThis study compares proton therapy to standard photon radiation for people with slow-growing brain tumors (IDH-mutated gliomas). The goal is to see if proton therapy, which targets tumors more precisely, can reduce side effects and maintain quality of life without shortening surv…
Sponsor: Oslo University Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
New pill shows promise in early brain tumor trial
Disease control Recruiting nowThis early-stage study tests an oral drug called ONC206 in adults with brain tumors that have come back. The main goal is to find the safest dose and check for side effects. About 102 participants will take the drug once or several times a week.
Phase 1 • Sponsor: Jazz Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC